Research Progress of Oxaliplatin in Drug Resistance of Gastric Cancer
Gastric cancer is one of the most common causes of cancer death in the world.Due to the biological differences between eastern and western countries,it is very difficult to determine a unified treatment standard.At present,there is no standard scheme for the treatment of advanced gastric cancer.Systemic chemotherapy,radiotherapy,surgery,immunotherapy and targeted therapy have been proved to be effective for gastric cancer.The main treatment of early gastric cancer is endoscopic resection,and late gastric cancer is treated with combined chemotherapy.With the rapid development of cytotoxic drugs and molecular targeted drugs,palliative chemotherapy for advanced gastric cancer has made some progress,and the median survival time of patients with advanced gastric cancer has been extended to about one year.Oxaliplatin combined with other drugs is recognized as a new choice for first-line chemotherapy of advanced gastric cancer.Due to the uncertain curative effect,safety problems and the emergence of tumor drug resistance,the role of molecular targeted drugs in the treatment of advanced gastric cancer needs further study.Therefore,this article reviews the research progress of oxaliplatin resistance in the treatment of gastric cancer.
万方数据
维普
